Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of CKD-501, D745, and D150 in Healthy Adults
NCT04334213Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone, empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 5 and Area Under the Curve over the Dosing Interval at Steady State at Day 5. Started May 2020; status: completed.
02
Drugs
lobeglitazoneempagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04334213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04334213.